? CANCER BIOLOGY (CB) The Cancer Biology (CB) Program at The Ohio State University Comprehensive Cancer Center (OSUCCC), led by Matthew Ringel, MD, and Philip Tsichlis, MD, has 56 members from 21 Departments and 5 OSU Colleges (Arts & Sciences, Engineering, Medicine, Public Health, and Veterinary Medicine). CB investigators focus on three thematic scientific areas of focus: 1) Defining the roles of non-coding RNAs, gene mutations, and regulation of gene expression in cancer development and progression; 2) Determining new mechanisms of altered cancer cell signal transduction and DNA damage repair responses, and responses to therapeutic challenges; and 3) integrating cancer biology into complex model systems, computational biology, and human tissues to study mechanisms of cancer progression. The overall vision of the CB Program is to exploit the fundamental mechanistic knowledge gained in these areas of strategic emphasis to improve cancer prevention, treatment, and outcomes through collaborations.
The Specific Aims of the CB Program focus on: 1) Mechanisms of cancer initiation. Studies focus on identification and characterization of mutations, epigenetic changes, and the expression and function of coding and non-coding genes. The goal will be to discover novel mechanisms of cancer predisposition and initiation, with an emphasis on translation; 2) Mechanisms and markers of response and resistance to therapeutic and environmental challenges. Research focuses on cancer responses to radiation and chemotherapy/targeted therapy with emphasis on signaling, DNA damage and the response to hypoxia and anti-tumor immunity; and, 3) Mechanisms of cancer progression. Studies focus on the identification of potentially targetable mechanisms that regulate tumor progression and metastasis. CB Program members published 645 cancer-relevant manuscripts between 12/01/14 and 11/30/19. Of these, 10% were intra- programmatic (multiple authors from CC Program), 25% were inter-programmatic (authors from multiple OSUCCC Programs), and 73% were multi-institutional (authors from both CB and another institution). The total collaborative publications is 81%. CB Program funding stands at $8.0M in overall direct, cancer-focused funding, of which $7.7M is peer-reviewed, including $6.7M direct funding from NIH ($5.1M from NCI). Over the last 5 years, CB Program members have accrued 1,522 participants to non-therapeutic/non-interventional trials comprised of investigator-driven IRB-approved biospecimen repositories. As a basic science program, CB is designed for member involvement in therapeutic trials through inter-programmatic collaboration. Future plans for the CB Program include innovation and growth in cancer immunology, translational genomics leveraging inter-institutional resources such as ORIEN, and identification of new targets, the development and growth of the cancer engineering research, and for cancer prevention by increasing basic science studies for the development of cancer and genetic predispositions.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10089993
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Lampis, Andrea; Carotenuto, Pietro; Vlachogiannis, Georgios et al. (2018) MIR21 Drives Resistance to Heat Shock Protein 90 Inhibition in Cholangiocarcinoma. Gastroenterology 154:1066-1079.e5
Le Gallo, Matthieu; Rudd, Meghan L; Urick, Mary Ellen et al. (2018) The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas. Cancer 124:65-73
Jones, Jeffrey A; Mato, Anthony R; Wierda, William G et al. (2018) Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol 19:65-75
Baldassari, Federica; Zerbinati, Carlotta; Galasso, Marco et al. (2018) Screen for MicroRNA and Drug Interactions in Breast Cancer Cell Lines Points to miR-126 as a Modulator of CDK4/6 and PIK3CA Inhibitors. Front Genet 9:174
Yang, Xiaosong; Pan, You; Qiu, Zhaojun et al. (2018) RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells. Clin Cancer Res 24:1629-1643
Ozawa, Patricia Midori Murobushi; Alkhilaiwi, Faris; Cavalli, Iglenir João et al. (2018) Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells. Breast Cancer Res Treat 172:713-723
Ngankeu, Apollinaire; Ranganathan, Parvathi; Havelange, Violaine et al. (2018) Discovery and functional implications of a miR-29b-1/miR-29a cluster polymorphism in acute myeloid leukemia. Oncotarget 9:4354-4365
Lopez, Cecilia M; Yu, Peter Y; Zhang, Xiaoli et al. (2018) MiR-34a regulates the invasive capacity of canine osteosarcoma cell lines. PLoS One 13:e0190086
Victor, Aaron R; Weigel, Christoph; Scoville, Steven D et al. (2018) Epigenetic and Posttranscriptional Regulation of CD16 Expression during Human NK Cell Development. J Immunol 200:565-572
Hankey, William; Chen, Zhong; Bergman, Maxwell J et al. (2018) Chromatin-associated APC regulates gene expression in collaboration with canonical WNT signaling and AP-1. Oncotarget 9:31214-31230

Showing the most recent 10 out of 2602 publications